Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy

[1]  Naveid A Ali,et al.  Global characterization of signalling networks associated with tamoxifen resistance in breast cancer , 2013, The FEBS journal.

[2]  A. Lykkesfeldt,et al.  Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling , 2013, Breast Cancer Research and Treatment.

[3]  P. Barbry,et al.  CDC25A targeting by miR-483-3p decreases CCND–CDK4/6 assembly and contributes to cell cycle arrest , 2013, Cell Death and Differentiation.

[4]  Kristina B. Emdal,et al.  NFκB signaling is important for growth of antiestrogen resistant breast cancer cells , 2012, Breast Cancer Research and Treatment.

[5]  E. Lerma,et al.  Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas , 2012, British Journal of Cancer.

[6]  J. Edwards,et al.  Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment , 2012, Journal of Cancer Research and Clinical Oncology.

[7]  C. Caldas,et al.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.

[8]  G. Mills,et al.  A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. , 2011, Cancer research.

[9]  R. Schiff,et al.  Biological mechanisms and clinical implications of endocrine resistance in breast cancer. , 2011, Breast.

[10]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[11]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[12]  G. Bhanot,et al.  Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. , 2010, Genes & cancer.

[13]  E. Mayer,et al.  Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies , 2010, Clinical Cancer Research.

[14]  R. Clarke,et al.  BCL2 and CASP8 regulation by NF‐κB differentially affect mitochondrial function and cell fate in antiestrogen‐sensitive and ‐resistant breast cancer cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  R. Salgia,et al.  Fyn: a novel molecular target in cancer. , 2010, Cancer.

[16]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[17]  I. Ellis,et al.  Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. , 2009, Cancer biology & therapy.

[18]  Ole N Jensen,et al.  Metastasis-related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.

[19]  A. Laenkholm,et al.  Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors , 2009, Breast Cancer Research.

[20]  B. Rasmussen,et al.  An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer , 2009, Acta oncologica.

[21]  M. Dowsett,et al.  ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. , 2008, Endocrine-related cancer.

[22]  V. Brunton,et al.  Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer , 2008, British Journal of Cancer.

[23]  Xin Wang,et al.  Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. , 2008, Cancer research.

[24]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  I. Ellis,et al.  Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer , 2007, Journal of Clinical Pathology.

[26]  J. Stenvang,et al.  Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells , 2007, Breast Cancer Research and Treatment.

[27]  R. Riggins,et al.  Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. , 2007, Cancer research.

[28]  Chin-Yo Lin,et al.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.

[29]  R. Nicholson,et al.  Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.

[30]  A. Lykkesfeldt,et al.  Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. , 2005, Endocrine-related cancer.

[31]  L. Klotz.  Can clinically localized prostate cancer be managed conservatively? , 2005, Nature Clinical Practice Urology.

[32]  N. Robert,et al.  Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. , 2005, MedGenMed : Medscape general medicine.

[33]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[34]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Boggon,et al.  Structure and regulation of Src family kinases , 2004, Oncogene.

[36]  R. Nicholson,et al.  Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells , 2004, Breast Cancer Research and Treatment.

[37]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[38]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[39]  Mitsugu Sekimoto,et al.  Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Yasuhiro Ito,et al.  Activation of c-Src is Inversely Correlated with Biological Aggressiveness of Breast Carcinoma , 2002, Breast Cancer Research and Treatment.

[41]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[42]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[44]  P. Briand,et al.  Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. , 1997, Cancer research.

[45]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[46]  M. Dowsett,et al.  Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. , 1995, Cancer research.

[47]  P. Briand,et al.  Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. , 1994, Cancer research.

[48]  J. Foekens,et al.  Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.

[49]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[50]  K. Gould,et al.  The absence of myristic acid decreases membrane binding of p60src but does not affect tyrosine protein kinase activity , 1986, Journal of virology.

[51]  P. Briand,et al.  Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. , 1986, British Journal of Cancer.

[52]  P. Briand,et al.  Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. , 1984, Cancer research.

[53]  R. Salgia,et al.  Fyn: a novel molecular target in prostate cancer , 2010 .

[54]  R. Gelber,et al.  Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.

[55]  J. Stenvang,et al.  Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. , 2007, Breast cancer research and treatment.

[56]  Vladimir B. Bajic,et al.  ERGDB: Estrogen Responsive Genes Database , 2004, Nucleic Acids Res..

[57]  P. Briand,et al.  Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways , 2001, Breast Cancer Research and Treatment.